The United States has introduced a 100% tariff on imports of patented pharmaceutical products and their ingredients following the completion of a Section 232 investigation into the industry. The measure will take effect in 120 days for large pharmaceutical companies and 180 days for smaller drugmakers, according to a White House fact sheet.
The policy applies specifically to patented medicines and related inputs, while several categories of pharmaceutical products are excluded. Generic and biosimilar medicines, along with their associated ingredients, are not subject to the tariffs. In addition, orphan drugs and certain specialty treatments may qualify for exemptions if they originate from countries with trade agreements or address urgent public health needs. Other exempted categories include cell and gene therapies and antibody-drug conjugates.
Multiple mechanisms have been outlined to reduce the tariff burden for pharmaceutical manufacturers. Imports from regions covered by existing trade agreements—including the European Union, Japan, Korea, Switzerland, and Liechtenstein—will face a reduced tariff rate of 15%. A separate agreement with the United Kingdom provides a full exemption for pharmaceutical exports to the U.S.
Companies that have entered into Most Favored Nation (MFN) pricing agreements with the administration are exempt from tariffs until January 20, 2029. Firms that have adopted onshoring arrangements may instead qualify for a reduced tariff rate of 20%. These provisions create several pathways for companies to limit exposure to the full tariff rate.
Large pharmaceutical companies have spent the past year preparing for potential tariff implementation, including committing to significant investments in domestic manufacturing. These pledges total hundreds of billions of dollars. Some companies have already reached agreements with the administration, although not all of these arrangements have resulted in immediate exemptions. Pfizer, Johnson & Johnson, and GSK have disclosed agreements but remain subject to near-term tariff timelines.
Other companies are still in the process of negotiating. Regeneron, which has not finalized an agreement, is listed among those expected to face tariffs within 120 days, although analysts have indicated that the company anticipates an exemption. The administration has also begun discussions with smaller drugmakers, and analysts have suggested that existing agreements may serve as models for future deals.
The structure of the policy has prompted responses from across the biotech sector, particularly among companies focused on innovative therapies. The Midsized Biotech Alliance of America (MBAA) stated that the framework may place a disproportionate burden on companies that rely on a limited number of patented medicines, especially those developing treatments in areas such as cancer and rare diseases.
The Biotechnology Innovation Organization (BIO) also raised concerns about the potential operational impact on drug development and manufacturing. John Crowley, the organization’s President and CEO, said, “tariffs on America’s medicines will raise costs, impede domestic manufacturing, and delay the development of new treatments, all while doing nothing to enhance our national security.” He further indicated that smaller and mid-sized biotechnology companies may face greater challenges due to high development costs, long timelines, and limited access to manufacturing infrastructure.
Industry groups representing generic and biosimilar manufacturers responded positively to the exemption of off-patent medicines, noting that these products will not be affected under the current policy. The administration has indicated that this exemption will be reviewed after one year.
Why the U.S. Targeted Patented Pharmaceutical Imports
The decision to impose tariffs on Patented Pharmaceutical products is part of a broader strategy to:
- Reduce high drug prices in the U.S.
- Encourage onshore manufacturing
- Strengthen national healthcare security
The policy specifically targets branded and Patented Pharmaceutical imports from companies that have not agreed to pricing reforms or U.S.-based production.
Key Features of the Patented Pharmaceutical Tariff Policy
The new Patented Pharmaceutical tariff framework includes several important elements:
- Up to 100% tariffs on imported patented drugs
- Phased implementation timelines for companies
- Incentives for domestic manufacturing investments
- Pressure to adopt “most favored nation” pricing models
